Sirturo
bedaquiline
Table of contents
Overview
Sirturo is a tuberculosis medicine that contains the active substance bedaquiline. Tuberculosis is an infection caused by the bacterium Mycobacterium tuberculosis.
Sirturo is used in combination with other tuberculosis medicines in adults and children (aged at least 5 years and weighing at least 15 kg) with tuberculosis in the lung that is multi-drug resistant (resistant to at least isoniazid and rifampicin, the two standard tuberculosis medicines). It is given when other combinations cannot be used, either because the disease is resistant to them or because of their side effects.
Tuberculosis is rare in the EU, and Sirturo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 26 August 2005. Further information on the orphan designation: EU/3/05/314.
-
List item
Sirturo : EPAR - Medicine overview (PDF/123.87 KB)
First published: 14/03/2014
Last updated: 13/07/2021
EMA/74439/2021 -
-
List item
Sirturo : EPAR - Risk-management-plan summary (PDF/123.11 KB)
First published: 14/03/2014
Last updated: 13/07/2021
Authorisation details
Product details | |
---|---|
Name |
Sirturo
|
Agency product number |
EMEA/H/C/002614
|
Active substance |
bedaquiline fumarate
|
International non-proprietary name (INN) or common name |
bedaquiline
|
Therapeutic area (MeSH) |
Tuberculosis, Multidrug-Resistant
|
Anatomical therapeutic chemical (ATC) code |
J04AK05
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Conditional approval |
This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Janssen-Cilag International NV
|
Revision |
21
|
Date of issue of marketing authorisation valid throughout the European Union |
05/03/2014
|
Contact address |
Turnhoutseweg 30 |
Product information
23/02/2023 Sirturo - EMEA/H/C/002614 - II/0051
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antimycobacterials
Therapeutic indication
Sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (MDR TB) in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Assessment history
News
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 202129/01/2021
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 201913/12/2019
-
21/03/2014
-
European Medicines Agency recommends approval of a new medicine for multidrug-resistant tuberculosis20/12/2013
-
20/12/2013